PT-141

Works on desire in the brain, not on blood flow. It began as a tanning peptide.

Evidence: AApproved what's this?
Grade A for low sexual desire in premenopausal women. Grade B for men.
Also known as: Bremelanotide · Vyleesi
Class: Cyclic heptapeptide; melanocortin-4 receptor agonist. Approved prescription medicine.

The 30-second version

WhatA refined cousin of Melanotan II, tuned for desire rather than tanning.

ResultsAbout 25% of women reported a meaningful lift in desire vs 17% on placebo. Real, but modest.

The honest catchNausea is common, and blood pressure briefly rises after each dose.

What it is

During Melanotan II tanning trials, male volunteers reported spontaneous erections. That side effect was refined into PT-141, which keeps the sexual effect and reduces the tanning. As Vyleesi it’s FDA-approved for acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women.

How it works

MC4 receptor in the hypothalamus is activated.

Desire pathway is switched on from the top down, at the level of wanting.

Not plumbing. Viagra and Cialis improve blood flow but do nothing for desire. PT-141 does the reverse.

On demand. Works through existing pathways, so normal use doesn’t cause a libido crash.

Overuse starts to hit MC1R, the pigment receptor, so skin darkening is the limiting factor.

What the research shows

RECONNECT: two identical Phase 3 trials in premenopausal women with HSDD. About 25% reported a meaningful improvement in desire, against about 17% on placebo. That’s statistically real and modest¹. In men: Phase 2 data support its use for erectile dysfunction and low desire, including in men who don’t respond to PDE5 drugs. Approval for men was never pursued, but off-label use is well established.

It isn’t a stronger Viagra. It acts on a different part of the problem.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Female HSDD	AApproved	~25% vs 17% meaningful improvement¹	Modest effect	Approved
Male ED and desire	BHuman trials	Effective, including PDE5 non-responders	Not approved for men	Established off-label
Central mechanism	AApproved	Acts on the brain’s desire pathway	—	Distinct from Viagra

Dosing: what has been reported

Not a recommendation. These figures describe what was studied or what circulates in practice, kept separate so you can see how solid each one is. Speak with a qualified clinician before acting on any of it.

Setting	Figure	Route	Grade
Approved (Vyleesi)	1.75 mg ≥45 min before activity; max 1 per 24 h and 8 per month	Subcutaneous	A
Off-label / community	Start 0.5–1 mg to gauge nausea, up to ~2 mg; 45 min to a few hours before	Subcutaneous	D

The effect lasts several hours. The intranasal form was abandoned because it caused worse blood-pressure spikes.

Preparing & storing

The approved product is an autoinjector. Compounded powder is reconstituted with bacteriostatic water and refrigerated.

Reported side effects

Nausea (~40% of women in trials), worst early and often easing with repeat use
Flushing (~20%), headache (~11%), injection-site reactions
Transient blood-pressure rise and heart-rate dip after each dose
Skin darkening (face, gums) with heavy or frequent use

Who should avoid it

Uncontrolled high blood pressure or cardiovascular disease
Naltrexone users (PT-141 reduces its effect; label interaction)
Combining with PDE5 inhibitors: only with a prescriber’s guidance
Pregnancy

Regulatory status checked Oct 2026

Body	Status	Detail
FDA (US)	Approved	Vyleesi (2019) for female HSDD; men off-label.
EMA (EU)	Not approved	—
CDSCO (India)	Not approved	Research and compounding channels only.
WADA	Not prohibited	Permitted in sport.

The NexGen read

A real desire drug, with honest trade-offs

PT-141 is approved and acts on wanting rather than mechanics. Its effect is moderate and nausea is common. Check your blood pressure first, start low, and don’t use it often.

References

Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899–908.
Vyleesi (bremelanotide) prescribing information. Palatin / AMAG. FDA approved June 2019.